利奈唑胺对多重耐药革兰氏阳性临床分离株的体外活性。
In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.
作者信息
Cercenado E, García-Garrote F, Bouza E
机构信息
Servicio de Microbiología, Hospital General Universitario 'Gregorio Marañón', Dr Esquerdo 46, 28007 Madrid, Spain.
出版信息
J Antimicrob Chemother. 2001 Jan;47(1):77-81. doi: 10.1093/jac/47.1.77.
The in vitro activity of the oxazolidinone linezolid was compared with the activities of vancomycin and teicoplanin against 450 Gram-positive clinical isolates, including a variety of multiply resistant strains. Linezolid inhibited all microorganisms tested at < or = 4 mg/L, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci and viridans streptococci, and erythromycin-resistant beta-haemolytic streptococci. The MIC(90) of linezolid for all isolates was 2 mg/L.
将恶唑烷酮类药物利奈唑胺的体外活性与万古霉素和替考拉宁对450株革兰氏阳性临床分离菌（包括多种多重耐药菌株）的活性进行了比较。利奈唑胺在≤4mg/L时可抑制所有测试的微生物，包括耐甲氧西林和耐替考拉宁的葡萄球菌、耐糖肽类肠球菌、耐青霉素和多重耐药的肺炎球菌及草绿色链球菌，以及耐红霉素的β溶血性链球菌。利奈唑胺对所有分离菌的MIC90为2mg/L。
Zotero 插件